Is OCTHF or JNJ a better dividend investment in 2026?

OCTHF currently yields 71428.57% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: OCTHF offers higher current income.

What is the dividend yield difference between OCTHF and JNJ?

OCTHF has a forward dividend yield of 71428.57% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 71426.44 percentage points.

Home › Compare › OCTHF vs JNJ

OCTHF vs JNJ: Dividend Comparison 2026

OCTHF yields 71428.57% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 OCTHF wins by $1.6804617092236922e+25M in total portfolio value

INVESTMENT

TIME HORIZON10 years

OCTHF

● Live price

71428.57%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1.6804617092236922e+25M

Annual income

$16,758,464,082,723,930,000,000,000,000,000.00

Full OCTHF calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — OCTHF vs JNJ

📍 OCTHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	OCTHF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, OCTHF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

OCTHF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCTHF

Annual income on $10K today (after 15% tax)

$6,071,428.57/yr

After 10yr DRIP, annual income (after tax)

$14,244,694,470,315,339,000,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, OCTHF beats the other by $14,244,694,470,315,339,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCTHF + JNJ for your $10,000?

OCTHF: 50%JNJ: 50%

100% JNJ50/50100% OCTHF

Portfolio after 10yr

$8.402308546118461e+24M

Annual income

$8,379,232,041,361,964,000,000,000,000,000.00/yr

Blended yield

99.73%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

OCTHF

No analyst data

Altman Z

-28.5

Piotroski

3/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCTHF buys

JNJ buys

No recent congressional trades found for OCTHF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricOCTHFJNJ

Forward yield	71428.57% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$1.6804617092236922e+25M	$30.3K ✓
Annual income after 10y	$16,758,464,082,723,930,000,000,000,000,000.00 ✓	$4,689.40
Total dividends collected	$1.6801590475897682e+25M	$15.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: OCTHF vs JNJ ($10,000, DRIP)

Year	OCTHF Portfolio	OCTHF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$7,153,557	$7,142,857.14	$10,592	$272.30	+$7.14M → OCTHF
2	$4,783,059,608	$4,775,405,302.31	$11,289	$357.73	+$4783.05M → OCTHF
3	$2,989,196,089,253	$2,984,078,215,471.53	$12,123	$472.89	+$2989196.08M → OCTHF
4	$1,746,108,740,720,723	$1,742,910,300,905,223.00	$13,141	$629.86	+$1746108740.71M → OCTHF
5	$953,366,906,359,837,700	$951,498,570,007,266,600.00	$14,408	$846.81	+$953366906359.82M → OCTHF
6	$486,546,837,026,708,500,000	$485,526,734,436,903,500,000.00	$16,021	$1,151.60	+$486546837026708.50M → OCTHF
7	$232,096,820,383,666,640,000,000	$231,576,215,268,048,070,000,000.00	$18,122	$1,588.22	+$232096820383666624.00M → OCTHF
8	$103,489,940,016,498,150,000,000,000	$103,241,596,418,687,620,000,000,000.00	$20,930	$2,228.20	+$103489940016498147328.00M → OCTHF
9	$43,133,653,750,454,530,000,000,000,000	$43,022,919,514,636,880,000,000,000,000.00	$24,792	$3,191.91	+$4.313365375045453e+22M → OCTHF
10	$16,804,617,092,236,920,000,000,000,000,000	$16,758,464,082,723,930,000,000,000,000,000.00	$30,274	$4,689.40	+$1.6804617092236922e+25M → OCTHF

OCTHF vs JNJ: Complete Analysis 2026

OCTHF — Stock

Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Full OCTHF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this OCTHF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCTHF vs SCHD OCTHF vs JEPI OCTHF vs O OCTHF vs KO OCTHF vs MAIN OCTHF vs ABBV OCTHF vs MRK OCTHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.